OKYO Pharma Reports Trial Results For Eye Pain Treatment

OKYO Pharma Limited reported positive findings from its Phase 2a trial of urcosimod (0.05%) for treating neuropathic corneal pain (NCP). The trial showed significant pain reduction and improvements in patient-reported quality of life measures, with results to be presented at the ARVO 2026 Annual Meeting. The study involved 12 weeks of treatment with urcosimod, where patients exhibited greater enhancements in emotional well-being compared to the placebo group.